J. Y. Feng

Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 that Exhibits Antiviral Efficacy in SARS-CoV-2 Infected African Green Monkeys

Interfering with nucleotide excision by the coronavirus 3'-to-5' exoribonuclease

This study investigates how SARS-CoV-2's ExoN enzyme processes RNA and identifies modifications that block its activity, offering potential for new antiviral strategies.

Characterization of a KDM5 Small Molecule Inhibitor with Antiviral Activity against Hepatitis B Virus

This study identifies a KDM5 inhibitor with anti-HBV activity in vitro but not in vivo, highlighting challenges in translating epigenetic therapies to viral infections.

Structural basis for substrate selection by the SARS-CoV-2 replicase

This study uses cryo-EM to reveal how the SARS-CoV-2 RTC discriminates between natural NTPs and the antiviral remdesivir triphosphate, providing insights for antiviral design.

Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir

This study investigates how remdesivir's antiviral activity varies across RNA viruses by analyzing its incorporation and inhibition mechanisms in different polymerases.

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

This paper evaluates the therapeutic efficacy of GS-621763, an oral prodrug of remdesivir, against SARS-CoV-2 in mice, showing reduced viral load and improved lung function.

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.